Objective To explore the effect of Pemetrexed Disodium and Docetaxel in combination with Nedaplatin in the treatment of advanced lung adenocarcinoma.Methods A total of 80 patients with advanced lung adenocarcinoma who were treated to our hospital from April 2017 to March 2019 were selected as the research objects.According to the random number table method, the research objects were divided into control group and study group, 40 cases in each group.The control group was treated with Docetaxel plus Nedaplatin.The study group was treated with Pemetrexed Disodium in combination with Nedaplatin.The treatment effect, T lymphocytes (CD3+、CD4+、CD8+、CD4+/CD8+) and total incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment between the two groups of patients was not statistically significant (P>0.05).After 4 cycles of chemotherapy, the CD3+,CD4+, CD4+/CD8+ of the two groups of patients were higher than those before chemotherapy, and CD8+ was lower than that before chemotherapy, and the CD3+, CD4+, CD4+/CD8+ of the study group were higher than those in the control group, and CD8+was lower than that in the control group, the differences were statistically significant (P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group, the difference was statistically significant (P<0.05).Conclusion The clinical effect of Pemetrexed Disodium and Docetaxel in combination with Nedaplatin in the treatment of advanced lung adenocarcinoma is comparable, but Pemetrexed Disodium combined with Nedaplatin can enhance the immune function of patients, less adverse reactions, worthy of clinical application.